Date: 2016-07-31
Type of information: Series C financing round
Company: InflaRX (Germany), international industrial investors, family offices, existing investors.
Investors: Staidson Hongkong Investment Company (China)
Amount: € 31 million ($ 34 million)
Funding type: series C financing round
Planned used:
- InflaRx is a biopharmaceutical company developing new therapeutics in the terminal complement space. Proceeds from the round will be used to advance clinical phase II development of IFX-1, a first-in- class monoclonal anti-complement C5a antibody, in various acute and chronic inflammatory indications as well as the preclinical development of the follow-up pipeline-molecules.
- In January 2016, InflaRx successfully completed its first clinical Phase IIa trial in patients suffering from early septic organ dysfunction; all primary clinical endpoints were met. In June 2016, the company initiated its second phase II trial of IFX-1 in patients undergoing complex cardiac surgery.
Others:
- • On July 21, 2016, InflaRx announced that it has raised €31 million ($34 million) in a Series C round. The financing was composed of new investors such as Staidson Hongkong Investment Company ltd. (“STS”), international industrial investors and family offices as well as existing investors.
Therapeutic area: Inflammatory diseases
Is general: Yes
